Interferon gamma release assays based on M. tuberculosis-specific antigens (IGRAs) in sarcoidosis patients

Kempisty, Anna; Białas-Chromiec, Beata; Borkowska, Dagmara; Kuś, Jan

doi:10.1183/13993003.congress-2015.pa3315

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cytology of needle aspiration specimens may reveal non‐necrotizing granulomas in both sarcoidosis patients as well as in a significant percentage of patients with TB lymphadenopathy . Finally, the interferon‐gamma release assays are generally negative in patients with sarcoidosis, but they can also be negative in up to 20% of patients with active TB . Interestingly, the tuberculin skin test (TST) is the most useful non‐invasive test for differentiating the two conditions.…”

Section: Why Has Ebus Become Invaluable For the Diagnosis Of Sarcoidomentioning

confidence: 99%

Endobronchial ultrasound‐guided transbronchial needle aspiration in sarcoidosis: Beyond the diagnostic yield

et al. 2019

View full text Add to dashboard Cite

Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is the commonly used technique for pathological confirmation of clinically suspected sarcoidosis, mostly owing to its consistently high success rate in the detection of granulomas. However, other possible advantages, which are less appreciated and often poorly studied, may also contribute to the wider use of EBUS-TBNA in the future. These advantages include refinement of differential diagnoses through the study of lymph node characteristics during B-mode examination; reduction of complications associated with bronchoscopy, as well as improved triage of the specimen for ancillary studies with the use of rapid on-site evaluation; optimization of the quality of the sample through the selection of a target area for biopsy with minimal vascularity and absence of calcifications by using the colour Doppler and the B-mode; and prediction of the presence of extensive lymph node fibrosis by using the strain elastography module. Yet, limitations and possible clinical drawbacks should also be acknowledged. Indeed, due to the lack of specificity of the pathology findings in EBUSderived samples, the diagnosis of sarcoidosis is one of the exclusion and should remain essentially clinical. The external validity of EBUS-TBNA results in sarcoidosis is questionable, as they mainly derive from studies in populations with a high disease prevalence. Finally, the risk exists that the low morbidity and high diagnostic yield of EBUS-TBNA may lead to its overuse in patients with clinical/radiological findings specific enough to secure a clinical diagnosis of sarcoidosis.

show abstract

Section: Why Has Ebus Become Invaluable For the Diagnosis Of Sarcoidomentioning

confidence: 99%

Endobronchial ultrasound‐guided transbronchial needle aspiration in sarcoidosis: Beyond the diagnostic yield

et al. 2019

View full text Add to dashboard Cite

show abstract

“…By contrast, in another study, the sensitivity was reported to be 87.5% whereas the specificity was 86% (25). In addition, there appeared to be a low rate of T-SPOT.TB positivity in patients with sarcoidosis regardless of the stage, where the possible mechanism may be associated with shared immune response (26). According to the WHO-consolidated guidelines on tuberculosis, Module 3: Diagnosis-Tests for tuberculosis infection (27), T-SPOT.TB can be used to test for tuberculosis infection but with exceptionally low certainty of evidence.…”

Section: Discussionmentioning

confidence: 84%

Sarcoidosis detected after COVID‑19 with T‑SPOT.TB positive: A case report

Wang,

Geng,

Liu

et al. 2023

Exp Ther Med

View full text Add to dashboard Cite

Sarcoidosis is an idiopathic multisystem disorder with unknown etiology. Due to clinical similarities among sarcoidosis, tuberculosis (TB) infection and malignant diseases (such as lymphoma, lung carcinoma and pituitary tumor), the diagnosis of sarcoidosis is challenging. The present report describes a case of sarcoidosis in a 48-year-old male with complaint of chest pain 1 month after Coronavirus disease 2019. The patient underwent whole-body 18 F-fluorodeoxyglucose ( 18 F-FDG) PET-CT imaging, which revealed multiple lymphadenopathies throughout the body without lung parenchyma involvement. Biochemical examinations such as T-SPOT.TB test and pathological examination of right supraclavicular lymph node revealed positive T-SPOT.TB but negative Ziehl-Neelsen staining. However, non-caseating epithelioid granulomas were observed in the mediastinal biopsy, indicating the diagnosis of sarcoidosis. The patient was clinically stable, and the symptom of chest pain was gradually relieved without any specific treatment. Outpatient follow-up continued every 3 months. The present case suggested a possible link between coronavirus infection and sarcoidosis, which suggests the advantages of 18 F-FDG PET-CT for the detection of sarcoidosis. However, T-SPOT.TB is insufficient for differentiating between sarcoidosis and TB.

show abstract

“…Moreover, in half of the patients with sarcoidosis, the response of CD4 and CD8 T cells from BALF to ESAT-6 was noticed [16]. However, Kempisty et al [12] found comparable IGRAs results for that of local population. So, from the diagnostic point of view, IFN-gamma assays, quite opposite to TST, seem to be reliable methods for detection of LTBI in sarcoidosis patients as well.…”

Section: Can Igras Be Helpful To Achieve This Goal?mentioning

confidence: 91%

“…In this issue of "Pneumonologia i Allergologia Polska", Kempisty et al [12] contribute to our knowledge of IGRAs spectrum in such patients. In their study of 151 patients, BCG vaccinated in the past with confirmed sarcoidosis, QFN-GIT was performed in all of them, while T-SPOT.TB only in a subgroup of subjects.…”

Section: Can Igras Be Helpful To Achieve This Goal?mentioning

confidence: 99%